TOP > 外国特許検索 > CANCER DIAGNOSIS KIT AND CANCER DIAGNOSIS METHOD

CANCER DIAGNOSIS KIT AND CANCER DIAGNOSIS METHOD

外国特許コード F100002328
掲載日 2010年12月14日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2008JP063002
国際公開番号 WO 2009034779
国際出願日 平成20年7月18日(2008.7.18)
国際公開日 平成21年3月19日(2009.3.19)
優先権データ
  • 特願2007-236048 (2007.9.12) JP
発明の名称 (英語) CANCER DIAGNOSIS KIT AND CANCER DIAGNOSIS METHOD
発明の概要(英語) Disclosed are a kit and a method for diagnosing cancer, each of which utilizes a polynucleotide comprising the nucleotide sequence depicted in SEQ ID NO: 1 or 3 or a partial sequence thereof, a polypeptide comprising the amino acid sequence depicted in SEQ ID NO: 2 or 4 or a partial sequence thereof, or an antibody capable of binding specifically to a polypeptide comprising the amino acid sequence depicted in SEQ ID NO: 2 or 4 or a partial sequence thereof. It becomes possible to find a CT antigen useful for the detection, diagnosis or treatment of cancer occurring in a digestive organ, and to develop a novel cancer diagnosis technique utilizing the CT antigen.
従来技術、競合技術の概要(英語) BACKGROUND ART
Cancer an effective inspection techniques, diagnostic methods and treatment method for establishing, and the high frequency of cancer target expressed stronger in a cancer antigen and the antigen can be found necessary. However, gastrointestinal cancer, in particular gastric cancer, colon cancer includes, inspection, few cancer antigens useful in the diagnostic or therapeutic. Therefore, the inspection of gastrointestinal cancer, a cancer antigen useful in the diagnostic or therapeutic is extremely important to develop.
Human cancer examination, diagnostic or treatment, from the viewpoint of side effects, is expressed in a variety of cancers, restricted to testis in normal tissues cancer, testis antigen (Cancer-Testis antigen, hereinafter 'CT antigen' hereinafter) is believed to be the most useful. To date, identified CT antigen of about 40, have been reported. However, all of these CT antigen to a cancer patient not have strong immunogenicity but, for cancer diagnosis, inspection marker, promising CT antigen or for the treatment of cancer is limited.
Reported current representative CT antigens include, (see non-patent document 1) MAGE, SSX (see non-patent document 2), NY-ESO-1 (see non-patent document 3) and the like. MAGE and NY-ESO-1 Western and about the clinical application, had the advantages of the present invention is obtained (for example, NY-ESO-1 and clinical application of non-patent document 4 for reference). In this way, the treatment of cancer is currently the most promising application to those NY-ESO-1 is considered.
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, Knuth A, Boon T.A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
Gure AO, Tureci O, Sahin U, Tsang S, Scanlan MJ, Jager E, Knuth A, Pfreundschuh M, Old LJ, Chen YT. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int. J. Cancer 72: 965-971, 1997.
Chen YT, Scanlan, MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94: 1914-1918, 1997.
Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. USA 97: 12198-12203, 2000.
Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I,Karbach J, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187:1349-1354, 1998.
Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth AA, Ritter G, Chen YT, Stockert E, Tsushima T, Kumon H, Old LJ, Nakayama E. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. 61: 4671-4674, 2001.
Nakada T, Noguchi Y, Sato S, Ono T, Saika T, Kurashige T, Gnjatic S, Ritter G, Chen YT, Stockert E, Nasu Y, Tsushima T, Kumon H, Old LJ, Nakayama E. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immunity 3: 10, 2003.
Sugita Y, Wada S, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, Scanlan MJ, Ono T, Sakita I, Yasui M, Miyoshi Y, Tamaki Y, Matsuura N, Noguchi S, Old LJ, Nakayama E, Monden M. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.Cancer Res. 64: 2199-2204, 2004.
Fujita S, Wada H, Jungbluth AA. Sato S, Nakata T, Noguchi Y, Doki Y, Yasui M, Sugita Y, Yasuda T, Yano M, Ono T, Chen YT, Higashiyama M, Gnjatic S, Old LJ, Nakayama E, Monden M. NY-ESO-1 expression and immunogenicity in esophageal cancer.Clin. Cancer Res. 10: 6551-6558, 2004.
Nakamura, S, Nouso K, Noguchi Y, Higashi T, Ono T, Jungbluth AA, Chen YT, Old LJ, Nakayama E, Shiratori Y. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 21: 1281-1285, 2006.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
  • 発明者(英語)
  • ONO, Toshiro
  • NAKAYAMA, Eiichi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MT NL NO PL PT RO SE SI SK TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close